Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL637086 | 0.85 | TSHR (0.41) | DYRK1AKDM4EALDH1A1HPGDTSHR | |
| SCHEMBL16587420 | 0.80 | DYRK1A (0.41) | DYRK1AKDM4EALDH1A1HPGDGAA | |
| SCHEMBL3228933 | 0.80 | DYRK1A (0.41) | DYRK1AKDM4EALDH1A1HPGDGAA | |
| SCHEMBL21484251 | 0.80 | TAAR1 (0.47) | DYRK1AKDM4EALDH1A1HPGDGAA | |
| SCHEMBL12490650 | 0.80 | DYRK1A (0.41) | DYRK1AKDM4EALDH1A1HPGDGAA | |
| Bromide SCHEMBL25374489 | 0.78 | DYRK1A (0.40) | DYRK1AKDM4EALDH1A1HPGDGAA | |
| SCHEMBL9770 | 0.78 | TAAR1 (0.50) | ALDH1A1GAANPSR1TAAR1AKR1B1 | |
| SCHEMBL30568075 | 0.78 | DYRK1A (0.42) | DYRK1AKDM4EHPGDTSHRSMN1; SMN2 | |
| SCHEMBL3053661 | 0.78 | TSHR (0.35) | DYRK1AKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL2780319 | 0.78 | DYRK1A (0.42) | DYRK1AKDM4EHPGDTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112654621-B | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. | 2024-01-04 | — | — | US | disclosed |
| EP-3814348-B9 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| EP-4204400-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | Fibrogen, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116348450-A | Compounds, compositions and methods for histone lysine demethylase inhibition | 菲布罗根有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
| WO-2022047230-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20210147427-A1 | PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE | LEAD DISCOVERY CENTER GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| WO-2007031828-A2 | THERAPEUTIC PYRROLIDINES | PFIZER PRODUCTS INC. (US) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007031828-A2 | THERAPEUTIC PYRROLIDINES | PFIZER PRODUCTS INC. (US) | 2007-03-22 | — | — | WO | disclosed |
| EP-1521744-A1 | ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS | LABORATOIRES FOURNIER S.A. (FR) | 2005-04-13 | — | — | EP | disclosed |
| WO-2003106428-A1 | NOVEL ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS THERAPEUTIC AGENTS | LABORATOIRES FOURNIER SA (FR) | 2003-12-24 | — | — | WO | disclosed |
| WO-2000078726-A1 | IMIDAZOLINE DERIVATIVES FOR THE TREATMENT OF DIABETES, ESPECIALLY TYPE II DIABETES | ELI LILLY AND COMPANY (US) | 2000-12-28 | — | — | WO | disclosed |
| US-5175164-A | Hypotensive agents | MERCK & CO., INC. (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0517357-A1 | Angiotensin II antagonists incorporating a substituted indole or dihydroindole | MERCK & CO. INC. (US) | 1992-12-09 | — | — | EP | disclosed |
| EP-0508723-A1 | Angiotensin II antagonists incorporating an indole or dihydroindole | MERCK & CO. INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| US-5151435-A | Hypotensive agents, glaucoma and cognition activators | MERCK & CO., INC. (US) | 1992-09-29 | — | — | US | disclosed |
| US-4244966-A | 1,3-Dihydro-3-(2-hydroxy-, 2-bromo- or 2-chloroethyl)-2H-isoindol-1-one derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | DYRK1A 495/4885KDM4E 1982/4885ALDH1A1 3814/4885 |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | DYRK1A 495/4885KDM4E 1982/4885ALDH1A1 3814/4885 |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | KDM5C, KDM5B, KDM5A | DYRK1A 3300/4885KDM4E 15/4885ALDH1A1 2449/4885 |
| US-20210147427-A1 | PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE | CDK1, CDK2, CDK15 | DYRK1A 575/4885KDM4E 1467/4885ALDH1A1 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.